Format

Send to

Choose Destination
World J Gastroenterol. 2012 Feb 21;18(7):698-703. doi: 10.3748/wjg.v18.i7.698.

Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.

Author information

1
Laboratory of Carcinogenesis and Translational Research for the Ministry of National Education, Department of GI Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142, China.

Abstract

AIM:

To investigate the efficacy and safety of imatinib dose escalation in Chinese patients with advanced gastrointestinal stromal tumor (GIST).

METHODS:

Advanced GIST patients previously failing 400 mg imatinib treatment were enrolled in this study. Patients received imatinib with dose escalation to 600 mg/d, and further dose escalation to 800 mg/d if imatinib 600 mg/d failed. Progression-free survival, overall survival, clinical efficacy, c-kit/PDGFRA genotype and safety were evaluated.

RESULTS:

52 patients were enrolled in this study. For the 47 evaluable patients receiving imatinib (600 mg/d), the disease control rate was 40.4%, and the median progression-free survival for all patients was 17 wk (95% CI: 3.9-30.1). The median overall survival after dose escalation was 81 wk (95% CI: 36.2-125.8). Adverse events, mainly edema, fatigue, granulocytopenia and skin rash were tolerable. However, further dose escalation (800 mg/d) in 14 cases was ineffective, with disease progression and severe adverse events. Among 30 cases examined for gene mutations, patients with exon 9 mutations experienced a better progression-free survival of 47 wk.

CONCLUSION:

Imatinib dose escalation to 600 mg/d is more appropriate for Chinese patients and may achieve further survival benefit.

KEYWORDS:

Gastrointestinal stromal tumor; Gene mutation; Imatinib; Increased dose

PMID:
22363143
PMCID:
PMC3281229
DOI:
10.3748/wjg.v18.i7.698
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center